Alumis (ALMS) Competitors $7.41 -0.25 (-3.26%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends ALMS vs. ARDX, NRIX, KNSA, RCUS, MRVI, OCUL, ARVN, CALT, DAWN, and SPRYShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Ardelyx (ARDX), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Maravai LifeSciences (MRVI), Ocular Therapeutix (OCUL), Arvinas (ARVN), Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Ardelyx Nurix Therapeutics Kiniksa Pharmaceuticals Arcus Biosciences Maravai LifeSciences Ocular Therapeutix Arvinas Calliditas Therapeutics AB (publ) Day One Biopharmaceuticals ARS Pharmaceuticals Alumis (NASDAQ:ALMS) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Is ALMS or ARDX more profitable? Alumis has a net margin of 0.00% compared to Ardelyx's net margin of -28.82%. Alumis' return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A N/A N/A Ardelyx -28.82%-46.60%-21.49% Do institutionals and insiders believe in ALMS or ARDX? 58.9% of Ardelyx shares are held by institutional investors. 5.9% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in ALMS or ARDX? Ardelyx received 518 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 67.47% of users gave Ardelyx an outperform vote. CompanyUnderperformOutperformAlumisOutperform Votes13100.00% Underperform VotesNo VotesArdelyxOutperform Votes53167.47% Underperform Votes25632.53% Which has better earnings and valuation, ALMS or ARDX? Alumis has higher earnings, but lower revenue than Ardelyx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/AN/AN/AN/AArdelyx$124.46M9.34-$66.07M-$0.30-16.37 Does the media refer more to ALMS or ARDX? In the previous week, Ardelyx had 9 more articles in the media than Alumis. MarketBeat recorded 9 mentions for Ardelyx and 0 mentions for Alumis. Ardelyx's average media sentiment score of 0.58 beat Alumis' score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media. Company Overall Sentiment Alumis Neutral Ardelyx Positive Do analysts recommend ALMS or ARDX? Alumis presently has a consensus price target of $26.83, suggesting a potential upside of 262.12%. Ardelyx has a consensus price target of $9.25, suggesting a potential upside of 88.39%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Ardelyx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryAlumis beats Ardelyx on 7 of the 13 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$349.90M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / SalesN/A335.351,284.8380.47Price / CashN/A22.6336.6032.90Price / BookN/A5.084.964.69Net IncomeN/A$154.90M$117.89M$224.57M7 Day Performance-3.01%2.59%2.74%3.33%1 Month Performance-15.99%1.52%3.63%5.33%1 Year PerformanceN/A5.49%27.26%22.97% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumisN/A$7.41-3.3%$26.83+262.1%N/A$349.90MN/A0.00N/APositive NewsARDXArdelyx3.675 of 5 stars$5.71+12.6%$9.25+62.0%-39.5%$1.35B$251.85M-19.0390NRIXNurix Therapeutics2.1666 of 5 stars$19.01+4.2%$30.35+59.7%+134.6%$1.35B$56.42M-6.53300Analyst ForecastKNSAKiniksa Pharmaceuticals2.9628 of 5 stars$18.03-9.5%$36.60+103.0%-1.8%$1.30B$384.10M-128.78220RCUSArcus Biosciences1.9 of 5 stars$13.80-2.8%$34.00+146.4%-8.8%$1.26B$263M-4.38500News CoverageMRVIMaravai LifeSciences4.5935 of 5 stars$5.00+3.1%$10.28+105.6%-23.7%$1.26B$276.92M-3.05610Gap UpOCULOcular Therapeutix3.6801 of 5 stars$7.97-2.9%$16.71+109.7%+108.1%$1.25B$61.44M-6.04267ARVNArvinas2.556 of 5 stars$17.72-4.8%$63.50+258.4%-50.4%$1.22B$161.10M-3.79420CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180DAWNDay One Biopharmaceuticals1.8184 of 5 stars$11.72-0.7%$35.86+205.9%-9.9%$1.18BN/A-11.3860SPRYARS Pharmaceuticals2.8814 of 5 stars$11.92+6.0%$24.50+105.5%+107.8%$1.16B$2.57M-23.3790 Related Companies and Tools Related Companies ARDX Alternatives NRIX Alternatives KNSA Alternatives RCUS Alternatives MRVI Alternatives OCUL Alternatives ARVN Alternatives CALT Alternatives DAWN Alternatives SPRY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALMS) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
